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Ezetimibe, which selectively inhibits cholesterol absorption across the intestinal wall and is used as an
antihyperlipidemic agent, is synthesized for commercial use as a drug substance in highly pure form.
During the synthetic process development studies of ezetimibe, an impurity was detected in the ﬁnal
product at levels ranging from 0.05% to 0.15% in reverse phase gradient high performance liquid chro-
matography (HPLC) method and its molecular weight was determined by LC–MS analysis. The impurity
was identiﬁed as (3R,4S)-3-((S)-3-(4-ﬂuorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-1-phenyla-
zetidin-2-one which is called desﬂuoro ezetimibe (lactam-related) impurity, synthesized and char-
acterized, the mechanism of its formation was discussed in detail. After all standardization procedures, it
was used as a reference standard during validation of HPLC method and routine analyses. In addition,
content of Eze-1 desﬂuoro impurity in Eze-1 intermediates was speciﬁed as 0.10% to keep the formation
of desﬂuoro ezetimibe impurity under control and the related substances HPLC method was validated
accordingly.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There are two recognized sources of cholesterol in the serum:
biosynthesis in the liver and absorption of dietary cholesterol in
the small intestine [1,2]. Statins inhibit 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase, the catalyst of the rate-
limiting step of cholesterol biosynthesis in the liver, and have been
prescribed as the predominant class of cholesterol-lowering
agents since 1980s [3]. Ezetimibe, (3R,4S)-1-(4-ﬂuorophenyl)-3-
((S)-3-(4-ﬂuorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)
azetidin-2-one (Scheme 1), has become an increasingly important
choice for reducing serum cholesterol level and it is the only
marketed example of this new class of anticholesterolemia drugs
[4,5]. Ezetimibe is a potent, metabolically stable cholesterol ab-
sorption inhibitor [6], which strongly blocks the absorption of
biliary and dietary cholesterol from the small intestine without
affecting the absorption of fat-soluble vitamins, triglycerides or
bile acids [7]. It may be used alone or together with statins (e.g.
ezetimibe/simvastatin) for the treatment of primary hypercholes-
terolemia, homozygous sitosterolemia, homozygous familial hy-
percholesterolemia, and mixed hyperlipidemia [8,9], and reduces
the risk of coronary heart disease [10].on and hosting by Elsevier B.V. All
University.
3; fax: þ90 282 7581770.
@yahoo.com (E. Bellur Atici).Organic and pharmaceutical chemists were attracted by the
novel structure and potent biological activity of ezetimibe, which
led to the development of several syntheses for this active phar-
maceutical ingredient (API) [11–17]. Few analytical methods have
been reported in the literature for the determination of ezetimibe
including studies on its pharmaceutical dosage forms and de-
gradation studies [18–21]. In recent years, studies related to
identiﬁcation, synthesis and characterization of process and de-
gradation related impurities, including stereoisomers of ezetimibe,
have been reported [22–28].
During high performance liquid chromatograph (HPLC) ana-
lyses of the drug substance ezetimibe, synthesized according to
the process given in Scheme 1 [16], one process related impurity
was observed consistently in the range of 0.05–0.15%. As per the
general guidelines recommended to qualify the drug substance by
International Conference on Harmonisation (ICH) [29,30], the ac-
ceptable level for a known and unknown related compounds
(impurity) should be less than 0.15% and 0.10%, respectively; and
the impurities present in the drug substance must be identiﬁed
and characterized. In recent years, the impurity proﬁle of a drug
substance becomes more important for marketing approval and
this work is done as part of a drug development process [31–35].
The impurity observed on HPLC analyses of ezetimibe was
identiﬁed by LC–MS studies as desﬂuoro ezetimibe, (3R,4S)-3-
((S)-3-(4-ﬂuorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-
1-phenylazetidin-2-one and pathway of its formation was clariﬁed
after thorough evaluation of the ezetimibe synthetic route. Therights reserved. This is an open access article under the CC BY-NC-ND license
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Scheme 1. Synthesis of ezetimibe and desﬂuoro ezetimibe impurity.
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related intermediates. All compounds synthesized in the scope of
this study were characterized by MS, IR and NMR (1H, 13C, DEPT,
19F). To the best of our knowledge, desﬂuoro ezetimibe impurities
were mentioned only in a few reports [36–39] and there is no
report in the literature on the identiﬁcation, synthesis and char-
acterization of the desﬂuoro impurity. As complementary of this
work, HPLC related substances methods for ezetimibe (Eze) and its
intermediate Eze-1 were validated and reported herein.2. Experimental
2.1. Chemicals, reagents and samples
Ezetimibe samples were taken from commercial batches pro-
duced by Deva Holding A.Ş. (Tekirdağ, Turkey), or synthesized in
the R&D laboratories of Deva. Ezetimibe standard was supplied by
a specialized team on standardization of reference standards for
analytical use in Deva. Synthetic and analytical reagents and sol-
vents were supplied from different chemical companies such as
Merck KGaA (Darmstadt, Germany), J.T. Baker (Phillipsburg, USA),
Sigma-Aldrich (St. Louis, MO, USA), Lab-Scan (Gliwice, Poland),
Acros Organics (Geel, Belgium), Akkim (Yalova, Turkey), Sodas
Sodyum Sanayi A.S. (Izmir, Turkey), and Emekcioglu Tuz A.S.
(Ankara, Turkey). All non-aqueous reactions were performed indry glassware under an atmosphere of dry nitrogen. Deionized
water was prepared using MilliQ plus puriﬁcation system (Milli-
pore, Bedford, MA, USA). Deuterated solvents (dimethylsulfoxide-
d6 and deuterated chloroform) were purchased from Merck KGaA
(Darmstadt, Germany).
2.2. Mass spectrometry
The mass spectra were recorded on Waters LC–MS ZQ 2000/
4000 system (Waters Corporation, Milford, MA, USA). The frag-
mentation proﬁle of the samples was established by carrying out
MS studies in the positive or negative electrospray ionization (ESI)
mode. For LC–MS identiﬁcation of the impurity, the HPLC method
given infra for ezetimibe related substances was used. The samples
of synthesized compounds were directly infused using a syringe at
a concentration of 1 mg/mL in acetonitrile.
2.3. NMR spectroscopy
1H, 13C and DEPT NMR experiments were performed on a
300 MHz NMR Spectrometer (Varian NMR Instruments, Oxford,
UK; later acquired by Agilent Technologies, Santa Clara, CA, USA)
using deuterated dimethylsulfoxide (DMSO-d6) and deuterated
chloroform (CDCl3) as a solvent and tetramethylsilane (TMS) as an
internal standard.
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Samples were measured as neat by Attenuated Total Re-
ﬂectance (ATR) on Shimadzu FTIR Spectrometer IR Prestige-21
(Shimadzu Corporation, Kyoto, Japan) in the range of 600–
4000 cm1 with 20 scans and 2 cm1 resolution. Melting ranges
of the samples were determined on an Electrothermal 9100 digital
melting point instrument (Thermo Fisher Scientiﬁc, Essex, UK).
2.5. HPLC
Chromatographic separations were performed on HPLC system
with Waters Alliance 2695 separation module equipped with a
Waters 996 photodiode array detector and an Empower-pro data
handling system (Waters Corporation, Milford, MA, USA).
The related substances analysis of ezetimibe was carried out on
Zorbax Rx C8 (0.25 m4.6 mm, 5 mm) column at 5 °C sample and
35 °C column temperatures. The injection volume and detection
wavelength were ﬁxed at 10 mL and 220 nm, respectively. Data was
acquired during 50 min by using gradient elution system ﬂowing
at a rate of 1.3 mL/min. Buffer solution was prepared by dissolving
2.71 g of potassium dihydrogen phosphate in 1000 mL of water
and pH was adjusted to 3.070.05 with 10% phosporic acid. Mix-
ture of buffer solution and acetonitrile (80:20) was used as mobile
phase A; and acetonitrile as diluent and mobile phase B. Test so-
lution was prepared by dissolving 25.0 mg of sample in 25.0 mL of
acetonitrile (1.0 mg/mL). Reference solution was prepared by dis-
solving 25.0 mg of ezetimibe reference standard (RS) in 25.0 mL of
acetonitrile, followed by dilution of 1.0 mL of this solution to
100.0 mL with acetonitrile, then dilution of 1.0 mL of the resulting
solution to 10.0 mL with acetonitrile (0.10% with respect to the test
solution, 0.001 mg/mL). Test solutions were injected freshly and
reference solution was stable up to 48 h at room temperature. The
separation was employed using gradient elution based on the
following program: time (min)/% of mobile phase B: 0/12, 5/12, 25/
62, 40/62, 41/12, 50/12. This analysis method was also used during
standardization of desﬂuoro ezetimibe.
The related substances analysis of Eze-1 was carried out on
Kromasil (or ACE) C18 (0.25 m4.6 mm, 5 mm) column with 10 mL
injection volume at a wavelength of 225 nm by using gradient
elution ﬂowing at a rate of 1.1 mL/min during 25 min. Column and
sample temperatures were 30 °C and 25 °C, respectively. Buffer
solution was prepared by dissolving 2.72 g of potassium dihydro-
gen phosphate in 1000 mL of water and pH was adjusted to
7.570.05 with 10% potassium hydroxide. Mixture of buffer solu-
tion and acetonitrile (60:40) was used as mobile phase A; and
acetonitrile as diluent and mobile phase B. Test solution was
prepared by dissolving 20.0 mg of the sample in 50.0 mL of acet-
onitrile (0.4 mg/mL). Reference solution was prepared by dissol-
ving 20.0 mg of Eze-1 RS in 50.0 mL of acetonitrile, followed by
dilution of 1.5 mL of this solution to 50.0 mL with acetonitrile, then
dilution of 1.0 mL of the resulting solution to 10.0 mL with acet-
onitrile (0.30% with respect to the test solution; 0.0012 mg/mL).
Reference and test solutions were found stable up to 48 h at room
temperature. The separation was employed using gradient elution
based on the following program: time (min)/% of mobile phase B:
0/0, 2/0, 15/35, 18/35, 20/0, 25/0. This analysis method was also
used during standardization of desﬂuoro Eze-1.
The related substances analysis of Eze-3 was carried out on
Zorbax Rx C8 (0.25 m4.6 mm, 5 mm) columnwith 20 mL injection
volume at a wavelength of 220 nm by using gradient elution
ﬂowing at a rate of 1.3 mL/min during 40 min. Column and sample
temperatures were 35 °C and 20 °C, respectively. Mobile phase A
was prepared by dissolving 2.74 g of potassium dihydrogen
phosphate in 1000 mL of water and pH was adjusted to 3.070.05
with 10% phosphoric acid. Acetonitrile was used as diluent andmobile phase B. Test solution was prepared by dissolving 10.0 mg
of the sample in 10.0 mL of acetonitrile (1.0 mg/mL) and reference
solution by dissolving 10.0 mg of Eze-3 RS in 50.0 mL of acetoni-
trile. Reference and test solutions were found stable up to 96 h at
room temperature. The separation was employed using gradient
elution based on the following program: time (min)/% of mobile
phase B: 0/30, 5/30, 30/70, 32/30, 40/30.
The related substances analysis of Eze-4 was carried out on
Zorbax Rx C8 (0.25 m4.6 mm, 5 mm) column with 10 mL injection
volume at a wavelength of 220 nm by using gradient elution
ﬂowing at a rate of 1.3 mL/min during 55 min. Column and sample
temperatures were 35 °C and 25 °C, respectively. Mobile phase A
was prepared by dissolving 2.74 g of potassium dihydrogen phos-
phate in 1000 mL of water and pH was adjusted to 7.570.05 with
10% potassium hydroxide. Acetonitrile was used as diluent and
mobile phase B. Test solution was prepared by dissolving 30.0 mg of
the sample in 10.0 mL of acetonitrile (3.0 mg/mL) and reference
solution by dissolving 10.0 mg of Eze-4 RS in 50.0 mL of acetonitrile
(0.2 mg/mL). Reference and test solutions were found stable up to
96 h at room temperature. The separation was employed using
gradient elution based on the following program: time (min)/% of
mobile phase B: 0/35, 2/35, 28/75, 46/75, 47/35, 55/35.
2.6. Ultra performance liquid chromatography (UPLC)
Chromatographic separations for Eze-5, 6, 7 and their related
substances were performed on Waters Acquity UPLC system
equipped with Waters TUV detector and Empower-pro data
handling system (Waters Corporation, Milford, MA, USA). The
analysis was carried out on ChromPEARL SH C18 (0.15 m2.0 mm,
1.7 μm) column with 2 mL injection volume at a wavelength of
220 nm by using gradient elution ﬂowing at a rate of 0.4 mL/min
during 33 min. Column and sample temperatures were 40 °C and
5 °C, respectively. Buffer solution was prepared by dissolving
1.36 g of potassium dihydrogen phosphate in 1000 mL of water
and pH was adjusted to 7.570.05 with 10% potassium hydroxide.
Mixture of buffer solution and acetonitrile (80:20) was used as
mobile phase A, and acetonitrile as diluent and mobile phase B.
Test solution was prepared by dissolving 25.0 mg of the sample in
25.0 mL of acetonitrile (1.0 mg/mL). Reference solution was pre-
pared by dissolving 25.0 mg of related reference standard in
25.0 mL of acetonitrile, followed by dilution of 0.5 mL of this so-
lution to 50.0 mL with acetonitrile (1.0% with respect to the test
solution; 0.01 mg/mL). Reference and test solutions were found
stable up to 48, 24 and 72 h at 5 °C, respectively. The separation
was employed using gradient elution based on the following
program: time (min)/% of mobile phase B: 0/38, 12/53, 15/63, 25/
88, 30/38, 33/38. Analyses of desﬂuoro Eze-5, 6, and 7 were carried
out by using this method.
2.7. Synthesis of ezetimibe and desﬂuoro ezetimibe impurity
2.7.1. Synthesis of Eze-1 and desﬂuoro Eze-1
4-Hydroxybenzaldehyde (1.0 equiv.) was dissolved in iso-
propanol at 60 °C under stirring. 4-Fluoroaniline or aniline
(1.0 equiv.) was added to the resulting solution and the mixture
was stirred at 60 °C for 3 h. The solution was allowed to cool to
ambient, during which the expected imine crystallized. The crys-
tals were ﬁltered out, washed with isopropanol and dried at room
temperature to obtain 4-((4-ﬂuorophenylimino)methyl)phenol
(Eze-1) or 4-((phenylimino)methyl)phenol (desﬂuoro Eze-1) as
yellowish crystalline powder with 82% and 85% yield, respectively.
2.7.2. Synthesis of Eze-4
Mixture of 3-[5-(4-ﬂuorophenyl)-1,5-dioxopentyl]-4-(S)-phenylox-
azolidin-2-one (Eze-3) (1.0 equiv.), methanol, trimethylorthoformate
Fig. 1. HPLC chromatogram of (A) ezetimibe spiked with desﬂuoro ezetimibe impurity (system suitability solution) and (B) Eze-1 spiked with desﬂuoro Eze-1 impurity and
other related impurities (system suitability solution).
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hydrate (pTSA) was heated and stirred until no trace of starting
material (Eze-3) was observed in the reaction mixture. After com-
pletion of the reaction, the mixture was concentrated to a deﬁned
volume, quenched by addition of N,N-diisopropylethylamine (DI-
PEA) and followed by cooling for crystallization. The product crys-
tals were ﬁltered, washed with methanol and dried under vacuum
to obtain Eze-4 as white to slightly yellowish crystalline powder
(83%).
2.7.3. Synthesis of Eze-5 and desﬂuoro Eze-5
Mixture of DIPEA (4.0 equiv.), benzyl chloroformate (CbzCl,
1.3 equiv.) and toluene was added into a cooled suspension of Eze-
1 or desﬂuoro Eze-1 (1.2 equiv.) in methylene chloride. In a sepa-
rate reaction vessel, titanium complex was prepared by mixing
titanium tetrachloride (0.9 equiv.) and titanium tetraisopropoxide
(0.3 equiv.) in methylene chloride under cooling. Solution of Eze-4(1.0 equiv.) in methylene chloride was added into the cooled Eze-2
(Cbz-protected Eze-1) or desﬂuoro-Eze-2 (Cbz-protected desﬂuoro
Eze-1) solution at 15 °C and it was followed by additional cool-
ing to 45 °C. The titanium complex mixture was added into this
solution at 45 °C and stirred for reaction. The reaction was
quenched by addition of acetic acid and aqueous solution of citric
acid, respectively. The synthesis was followed by warming up the
reaction mixture to 25 °C, work-up and crystallization processes to
obtain Eze-5 or desﬂuoro Eze-5 as white to slightly yellowish
crystalline powder with 49% and 35% yield, respectively.
2.7.4. Synthesis of Eze-6 and desﬂuoro Eze-6
Dimethyl sulﬁde borane (1 M in methylene chloride, BH3.Me2S)
and (R)-2-Me-CBS oxazaborolidine (1 M in toluene) Corey–Bakshi–
Shibata catalyst mixture was prepared in methylene chloride. So-
lution of Eze-5 or desﬂuoro Eze-5 (1.0 equiv.) in methylene
chloride was added into the catalyst mixture. After completion of
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Fig. 2. Structures of ezetimibe, desﬂuoro impurity and intermediates.
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eous solution of hydrochloric acid (1.0 M), respectively. The
synthesis was followed by work-up and crystallization processes
to obtain Eze-6 or desﬂuoro Eze-6 as white to slightly yellowish
crystalline powder with 79% and 82% yield, respectively.
2.7.5. Synthesis of Eze-7 and desﬂuoro Eze-7
Lithium perchlorate (0.1 equiv.) and hexamethyldisilazane
(HMDS, 0.9 equiv.) were added into the solution of Eze-6 ordesﬂuoro Eze-6 (1.0 equiv.) in methylene chloride at room tem-
perature. After stirring for a deﬁned time period and completion of
the reaction, it was quenched by addition of water. The synthesis
was followed by work-up and crystallization processes to obtain
Eze-7 or desﬂuoro Eze-7 as white to slightly yellowish crystalline
powder with 90% and 94% yield, respectively.
2.7.6. Synthesis of ezetimibe and desﬂuoro ezetimibe
Solution of Eze-7 or desﬂuoro Eze-7 (1.0 equiv.) in
Table 1
Purity, melting range, FTIR and mass spectral data.
Compounda Purity (%) Melting range
(°C)
IR (neat, cm1) MS m/z
Eze-1 99.5b 18373 3048 (w), 2913 (w), 2872 (w), 2794 (w), 2735 (w), 2674 (w), 2593 (w), 2480 (w), 1605 (m), 1593 (s), 1575
(s), 1515 (m), 1500 (s), 1444 (s), 1287 (s), 1236 (s), 1186 (s), 1163 (s), 1151 (s), 1098 (m), 980 (m), 842 (s),
821 (s), 763 (s).
216 (þ)
Desﬂuoro-Eze-1 99.2 19473 3047 (w), 2914 (w), 2860 (w), 2795 (w), 2731 (w), 2673 (w), 2586 (w), 2476 (w), 1602 (m), 1575 (s), 1515
(m), 1484 (s), 1443 (s), 1284 (s), 1241 (s), 1189 (s), 1163 (s), 1151 (s), 1111 (w), 978 (m), 840 (s), 758 (s), 690
(s).
198 (þ)
Eze-4 99.4 8273 2959 (w), 2832 (w, C–H), 1800 (m), 1778 (s), 1703 (s, C¼O), 1385 (s), 1329 (m), 1275 (s), 1215 (s), 1198
(m), 1155 (m), 1130 (m), 1115 (m), 1088 (m), 1061 (s), 1038 (s), 953 (s), 831 (s), 756 (s), 698 (s).
400 ()
Eze-5 99.4 17673 3327 (w, N–H), 2960 (w, C–H), 1787 (s), 1748 (s), 1737 (s, C¼O), 1687 (s), 1679 (s), 1597 (m), 1513 (s), 1506
(s), 1369 (m), 1322 (m), 1264 (s), 1222 (s), 1214 (s), 1199 (s), 1156 (m), 1100 (s), 1084 (m), 1065 (m), 1039
(m), 980 (m), 845 (m), 828 (s), 758 (s), 707 (s).
705 (þ)
Desﬂuoro-Eze-5 86.8 13573 3382 (w, N–H), 2910 (w, C–H), 1780 (s), 1755 (s, C¼O), 1680 (s), 1599 (m), 1506 (s), 1382 (m), 1326 (m),
1317 (m), 1247 (s), 1228 (s), 1209 (s), 1164 (m), 1102 (m), 1064 (m), 748 (s), 698 (s).
687 (þ)
Eze-6 99.6 16373 3536 (w, O–H), 3346 (w, N–H), 3064 (w), 2964 (w), 2918 (w, C–H), 1777 (s), 1754 (s, C¼O), 1683 (s), 1511
(s), 1390 (m), 1377 (s), 1289 (s), 1261 (s), 1209 (s), 1102 (m), 1072 (m), 1060 (s), 841 (s), 829 (s), 690 (s).
707 (þ)
Desﬂuoro-Eze-6 94.8 12473 3564 (w, O–H), 3382 (w, N–H), 2918 (w, C–H), 1764 (s), 1756 (s, C¼O), 1683 (s), 1603 (m), 1508 (s), 1384
(m), 1325 (m), 1239 (s), 1206 (s), 1105 (m), 1063 (m), 836 (m), 748 (s), 699 (s).
689 (þ)
Eze-7 99.7 18473 3345 (w, N–H), 2964 (w), 2927 (w), 2864 (w, C–H), 1773 (s, C¼O), 1684 (m), 1507 (s), 1390 (m), 1378 (m),
1253 (s), 1216 (s), 1206 (s), 1105 (m), 1090 (m), 983 (m), 885 (m), 848 (m), 828 (s), 776 (m), 762 (m), 751
(m), 738 (s), 693 (s).
779 (þ)
Desﬂuoro-Eze-7 97.1 17473 3382 (w, N–H), 3036 (w), 2964 (w), 2900 (w, C–H), 1780 (s), 1768 (s), 1761 (s, C¼O), 1687 (s), 1602 (m),
1507 (s), 1377 (m), 1327 (m), 1262 (m), 1236 (s), 1224 (s), 1208 (s), 1172 (m), 1106 (s), 1081 (s), 1036 (m),
982 (m), 887 (m), 843 (s), 833 (s), 747 (s), 691 (s).
761 (þ)
Ezetimibe 99.9c 16373 3455 (br), 3273 (br, O–H), 2927 (w, C–H), 1727 (s, C¼O), 1596 (w), 1509 (s), 1448 (w), 1399 (m), 1353 (m),
1224 (s), 1212 (s), 1172 (s), 1161 (s), 1154 (s), 1140 (m), 1101 (m), 1007 (s), 937 (m), 829 (s), 822 (s).
410 (þ)
Desﬂuoro-ezetimibe 97.9 13173 3418 (br, O–H), 3036 (w), 2909 (w, C–H), 1714 (s, C¼O), 1599 (m), 1503 (s), 1403 (s), 1394 (m), 1226 (s),
1170 (m), 1157 (m), 1072 (m), 1009 (w), 834 (s), 748 (s), 687 (s).
392 (þ)
a Copies of spectra are presented in Appendix A.
b 0.08% desﬂuoro Eze-1 content.
c 0.05% desﬂuoro ezetimibe content.
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lyl)acetamide (BSA, 2.1 equiv.) and catalytic amount of tetra-
butylammonium hydroxide (TBAH, 50% in methanol) were added
into this mixture and stirred for a deﬁned time. After completion
of the reaction, it was quenched by addition of acetic acid and
concentrated by distillation. Methanol, acetic acid and catalytic
amount of Pd/C catalyst (5%) were added into the residue and
stirred in the presence of hydrogen (H2) gas. After completion of
the reaction, the mixture was ﬁltered, concentrated to a deﬁned
volume and crystallized to obtain crude ezetimibe. The synthesis
was followed by recrystallization and drying processes to obtain
ezetimibe or desﬂuoro ezetimibe in highly pure form as white to
off-white crystalline powder with 60% and 48% yield, respectively.3. Results and discussion
3.1. Ezetimibe and desﬂuoro ezetimibe syntheses
Ezetimibe is a β-lactam type hypolipidemic agent bearing three
chiral centers. Of these, two are located on the β-lactam ring while
the last one (alcohol) is present in the side chain. The molecule is
manufactured as a single enantiomer with absolute stereo-
chemistry (2R,11S,5S). The enantioselective determination of the
opposite OH-enantiomer, which is likely to be detected in the ﬁnal
API, is an integral part of the ezetimibe speciﬁcation. A validated
chiral HPLC method was used to control this enantiomer with the
acceptance limit of not more than 0.15%.
The stereochemistry issues are important for ensuring the
production of diastereo as well as enantiopure ﬁnal API. Ezetimibe
and desﬂuoro ezetimibe were synthesized according to the reac-
tion steps given in Scheme 1. Ketone functionality of Eze-3 was
protected by using trimethyl orthoformate and catalytic amount of
p-toluenesulfonic acid to form dimethyl ketal Eze-4.Corresponding Eze-1 imines (Schiff base) were prepared by reac-
tion of 4-hydroxybenzaldehyde and 4-ﬂuoroaniline or aniline and
then protected by reaction with benzyl chloroformate under basic
conditions to obtain Eze-2 or desﬂuoro Eze-2 intermediates, re-
spectively. Highly exothermic coupling reaction of protected imi-
nes (Eze-2 or desﬂuoro Eze-2) and Eze-4 was done under strong
cooling by using titanium complex (Ti(OiPr)Cl3) prepared by
mixing titanium tetrachloride and titanium tetraisopropoxide
with the ratio of 3:1. The reaction was quenched by acid addition,
and ketal deprotection was done by further acid treatment in situ
to obtain crystalline Eze-5 or desﬂuoro Eze-5.
Chiral centers C-2 and C-11 were created by diastereoselective
addition of optically active titanium enolate of Eze-4 to C¼N
double bond of Cbz-protected imine Eze-2. Chirality of ox-
azolidide-ketone Eze-4 induces chirality of both C-2 and C-11
chiral centers during the coupling reaction of Eze-2 and Eze-4
intermediates. Thus, it is highly important to have this inter-
mediate with high optical purity. For this reason, optical purity of
Eze-3 was controlled and a limit for content of its enantiomer was
set as not more than 0.10% and reference standard of Eze-3 en-
antiomer was prepared. Oxazolidide-acetal Eze-4 was treated with
a strong base DIPEA to generate an enolate which by action of Ti
(OiPr)Cl3 formed Ti(IV)-enolate of Eze-4. The latter exists due to
steric bulkiness of phenyl group on oxazolidinone ring exclusively
in (Z)-conﬁguration. Imine Eze-2 is (E)–conﬁgured and binds to Ti-
enolate, thus forming essentially sterically less hindered and
sterically more hindered complexes. In both cases, imine is located
below the plane of enolate, which deﬁnes absolute conﬁguration
at C-2. Accordingly, only two diastereoisomeric products were
formed in this reaction step with highly prevailing as expected (6–
8:1). Both primary products were hydrolyzed in situ by acids
forming ketone Eze-5 and its diastereoisomer. Luckily, minor and
unwanted diastereoisomer of Eze-5 is much more soluble and
single crystallization was sufﬁcient to reduce its content.
Fig. 3. UPLC chromatograms of (A) Eze-5, (B) Eze-6, and (C) Eze-7 spiked with their related desﬂuoro impurities.
E. Bellur Atici, B. Karlığa / Journal of Pharmaceutical Analysis 5 (2015) 356–370362The chiral center bearing hydroxyl group (C-5) was created by
applying Corey–Bakshi–Shibata (CBS) protocol to Eze-5 inter-
mediates to obtain the corresponding Eze-6 alcohols, namely re-
duction of ketone with borane dimethyl sulﬁde complex in the
presence of (R)-2-Me-CBS oxazaborolidine ((R)-hexahydro-1-methyl-3,3-diphenylpyrrolo[1,2]-c[1,3,2]oxazaborole) as a chirality
inductor. The enantioselective reduction of Eze-5 provided highly
predominating alcohol Eze-6 accompanied by minor amounts of
epimeric alcohol epi-Eze-6 with the amount of maximum 4%. The
content of the latter compound was set to not more than 3.0% and
Table 2
1H and 13C NMR assignments for Eze-1 and desﬂuoro Eze-1.
Positiona 1H–δ ppm 13C–δ ppm (DEPT)
Eze-1b Desﬂuoro
Eze-1b
Eze-1b Desﬂuoro
Eze-1b
1 10.15 (br, OH) 10.13 (br, OH) – –
2 – – 161.3 (C) 161.3 (C)
3 6.87 (d,
J¼8.5 Hz, 2H)
6.87 (dd, J¼8.4,
1.8 Hz, 2H)
116.3 (2CH) 116.3 (2CH)
4 7.74 (d,
J¼8.5 Hz, 2H)
7.75 (dd, J¼8.4,
1.8 Hz, 2H)
131.4 (2CH) 131.4 (2CH)
5 – – 128.1 (C) 128.2 (C)
6 8.43 (s, 1H) 8.43 (s, 1H) 160.8 (CH) 160.8 (CH)
7 – – 149.0 (d,
4J¼2.6 Hz, C)
152.7 (C)
8 7.15–7.26 (m,
4H)
7.36 (dd, J¼8.1,
7.5 Hz, 2H)
123.3 (d,
3J¼8.4 Hz, 2CH)
121.6 (2CH)
9 7.17 (d,
J¼7.8 Hz, 2H)
116.5 (d,
2J¼22 Hz, 2CH)
129.8 (2CH)
10 – 7.18 (t,
J¼6.3 Hz, 1H)
160.8 (d,
1J¼242 Hz, C)
126.0 (CH)
Assignments: s: singlet; d: doublet; t: triplet; m: multiplet; br: broad singlet. Mean
values used for coupled signals.
a Numbering of all compounds shown in Fig. 2 and copies of NMR spectra are
presented in Appendix A.
b Solvent is DMSO-d6.
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presence of (S)-2-Me-CBS oxazaborolidine. By using solubility
differences of epimers, content of minor epimeric alcohol was
further decreased by recrystallization of Eze-6 in methanol. Of
course, diastereomeric impurity of ketone Eze-5 also underwentTable 3
1H and 13C NMR assignments for Eze-4, ezetimibe and desﬂuoro ezetimibe.
Positiona 1H-δ ppm
Eze-4c Ezetimibeb Desﬂuoro
ezetimibeb
1 – – –
2 2.81 (dt, J¼7.5, 3.0 Hz, 2H) 3.04–3.08 (m, 1H) 3.03 (br, 1H)
3 1.22–1.33 (m, 2H) 1.60–1.83 (m, 2H) 1.60–1.83 (m, 2H
4 1.83–1.90 (m, 2H) 1.60–1.83 (m, 2H) 1.60–1.83 (m, 2H
5 – 4.47 (m, 1H) 4.45 (br, 1H)
6 – – –
7 7.25 (dd, J¼8.1, 1.8 Hz, 2H) 7.07–7.31 (m, 2H) 7.06–7.29 (m, 2H
8 7.00 (dt, J¼8.7, 1.8 Hz, 2H) 6.74 (d, J¼8.4 Hz,
2H)
6.72 (d, J¼8.1 H
2H)
9 – – –
10 3.11 (s, 3H) 5.28 (d, J¼4.5 Hz,
1H)
5.26 (br, 1H)
11 3.09 (s, 3H) 4.79 (d, J¼2.1 Hz,
1H)
4.77 (br, 1H)
12 – – –
13 4.25 (dd, J¼9.0, 3.6 Hz, 1H); 4.65 (t,
J¼9.0 Hz, 1H)
7.07–7.31 (m, 4H) 7.06–7.29 (m, 4H
14 5.36 (dd, J¼8.4, 3.6 Hz, 1H)
15 – – –
16 7.32–7.42 (m, 5H) 9.53 (s, 1H) 9.50 (s, 1H)
17 – –
18 7.07–7.31 (m, 4H) 7.06–7.29 (m, 4H
19 –
20 – – 6.98 (t, J¼7.2 H
1H)
Assignments: s: singlet; d: doublet; t: triplet; m: multiplet; br: broad singlet. Mean val
a Numbering of all compounds shown in Fig. 2 and copies of NMR spectra are pres
b Solvent is DMSO-d6.
c Solvent is CDCl3.reduction to corresponding alcohols. However, the content of such
alcohols, which was already low, was further decreased by crys-
tallization of the reaction product Eze-6.
In the following step, TMS protection of alcohol moiety of Eze-6
intermediates was done by reaction with HMDS under catalysis of
lithium perchlorate to form corresponding Eze-7 intermediates
and puriﬁed by crystallization which enhanced the stereochemical
purity further. In the last complex step, trans-β-lactam ring was
closed ﬁrst by the action of BSA and catalytic amount of TBAH
upon Eze-7 intermediates. The formation of cis-β-lactam that
would originate from silyl-ether originating from epimeric Eze-5
was much more sluggish. This implies that the formation of
measurable quantities of ezetimibe stereoisomer with 2R,11R,5S
conﬁguration as an impurity in ﬁnal API is highly improbable. The
formed 2-azetidinone intermediates reacted without isolation
further for Cbz- and TMS-deprotections by Pd/C catalyzed hydro-
genation under acidic conditions to obtain crude ezetimibe or
desﬂuoro ezetimibe. Furthermore, products were crystallized so
that the content of such an impurity with 2R,11R,5S conﬁguration,
if any formed, was further reduced. 2,11-epimer and enantiomer of
ezetimibe with 2S,11R,5S and 2S,11R,5R conﬁgurations, respec-
tively, would be only hypothetical products of CBS-reduction of
very improbable diastereomeric form of ketone Eze-5. 5-Epimer of
ezetimibe with 2R,11S,5R conﬁguration and called ezetimibe OH-
isomer was more likely to be detected in manufactured API as it
was formed from epimer of Eze-6 via epimer of Eze-7. Accordingly,
this stereoisomer was prepared and routinely tested for its pre-
sence in ﬁnal API (limit not more than 0.15%). Ezetimibe and
desﬂuoro ezetimibe were ﬁnally recrystallized to reach pharma-
ceutically acceptable purity and highly pure product to be used as
reference standard during validation of related substances HPLC13C-δ ppm (DEPT)
Eze-4c Ezetimibeb Desﬂuoro ezetimibeb
172.5 (C) 168.1 (C) 168.3 (C)
35.4 (CH2) 60.1 (CH) 59.9 (CH)
) 18.3 (CH2) 25.2 (CH2) 25.3 (CH2)
) 36.5 (CH2) 37.1 (CH2) 37.1 (CH2)
103.2 (C) 71.8 (CH) 71.7 (CH)
136.6 (d, 4J¼3.2 Hz, C) 142.9 (d, 4J¼2.9 Hz, C) 142.9 (d, 4J¼2.9 Hz, C)
) 129.0 (d, 3J¼7.7 Hz,
2CH)
128.2 (d, 3J¼6.2 Hz,
2CH)
128.2 (d, 3J¼7.7 Hz,
2CH)
z, 115.1 (d, 2J¼21 Hz,
2CH)
115.4 (d, 2J¼21 Hz,
2CH)
115.4 (d, 2J¼21 Hz,
2CH)
162.5 (d, 1J¼245 Hz, C) 161.7 (d, 1J¼241 Hz, C) 161.7 (d, 1J¼240 Hz, C)
48.8 (CH3) – –
48.8 (CH3) 60.3 (CH) 60.0 (CH)
154.0 (C) 128.6 (C) 128.8 (C)
) 70.2 (CH2) 128.25 (2CH) 128.19 (2CH)
57.7 (CH) 116.4 (2CH) 116.4 (2CH)
139.3 (C) 158.1 (C) 158.0 (C)
126.1 (2CH) – –
129.4 (2CH) 134.7 (d, 4J¼2.0 Hz, C) 138.2 (C)
) 129.0 (CH) 119.0 (d, 3J¼7.7 Hz,
2CH)
117.3 (2CH)
– 116.6 (d, 2J¼22 Hz,
2CH)
129.7 (2CH)
z, – 158.7 (d, 1J¼239 Hz, C) 124.1 (CH)
ues used for coupled signals.
ented in Appendix A.
Table 4
1H NMR assignments for intermediates of ezetimibe and desﬂuoro ezetimibe impurity.
Positiona δ ppm
Eze-5b Desﬂuoro Eze-5b Eze-6b Desﬂuoro Eze-6b Eze-7b Desﬂuoro Eze-7b
2 4.19 (dd, J¼8.7, 3.6 Hz,
1H)
4.14–4.17 (m, 1H) 4.18 (dd, J¼8.7, 3.3 Hz,
1H)
4.15 (dd, J¼8.7, 3.6 Hz,
1H)
4.24 (dd, J¼8.7, 3.3 Hz,
1H)
4.26 (dt, J¼8.4, 3.0 Hz,
1H)
3 1.79–1.90 (m, 1H); 2.16–
2.28 (m, 1H)
1.85–1.96 (m, 1H);
2.19–2.30 (m, 1H)
1.45–1.54 (m, 1H); 1.58–
1.82 (m, 1H)
1.48–1.60 (m, 1H); 1.61–
1.81 (m, 1H)
1.44–1.53 (m, 1H); 1.58–
1.74 (m, 1H)
1.42–1.59 (m, 1H);
1.60–1.78 (m, 1H)
4 2.90 (dt, J¼7.1, 1.2 Hz,
2H)
2.85–2.97 (m, 2H) 1.58–1.82 (m, 2H) 1.61–1.81 (m, 2H) 1.58–1.74 (m, 2H) 1.60–1.78 (m, 2H)
5 – – 4.51–4.60 (m, 1H) 4.51–4.59 (m, 1H) 4.54 (t, J¼5.7 Hz, 1H) 4.50–4.62 (m, 1H)
7 7.88 (dd, J¼8.7, 5.4 Hz,
2H)
7.86–7.90 (m, 2H) 7.16–7.27 (m, 2H) 6.96–7.08 (m, 2H) 7.04 (t, J¼8.7 Hz, 2H) 7.12–7.21 (m, 2H)
8 6.75 (t, J¼8.7 Hz, 2H) 6.96–7.19 (m, 2H) 6.76 (t, J¼8.7 Hz, 2H) 6.96–7.08 (m, 2H) 6.83 (t, J¼8.7 Hz, 2H) 7.06 (dt, J¼8.4, 2.4 Hz,
2H)
10 5.06 (d, J¼9.9 Hz, 1H) 5.18 (d, J¼8.1 Hz, 1H) 5.05 (d, J¼10.2 Hz, 1H) 5.21 (d, J¼9.9 Hz, 1H) 5.08 (d, J¼9.9 Hz, 1H) 5.27 (d, J¼7.8 Hz, 1H)
11 4.47 (t, J¼8.7 Hz, 1H) 4.55–4.66 (m, 1H) 4.40 (t, J¼9.3 Hz, 1H) 4.49 (t, J¼7.8 Hz, 1H) 4.44 (t, J¼9.9 Hz, 1H) 4.73 (t, J¼8.4, 2.4 Hz,
1H)
13 7.37–7.46 (m, 2H) 7.38–7.43 (m, 2H) 7.39–7.48 (m, 2H) 7.36–7.49 (m, 2H) 7.44–7.54 (m, 2H) 7.47–7.56 (m, 2H)
14 7.02–7.26 (m, 2H) 6.96–7.19 (m, 2H) 7.01 (t, J¼8.7 Hz, 2H) 7.16–7.25 (m, 2H) 7.09–7.27 (m, 2H) 7.23–7.28 (m, 2H)
18 7.37–7.46 (m, 2H) 6.47 (d, J¼6.9 Hz, 2H) 7.39–7.48 (m, 2H) 6.44 (d, J¼7.8 Hz, 2H) 7.44–7.54 (m, 2H) 6.55 (d, J¼6.6 Hz, 2H)
19 6.38 (dd, J¼8.7, 4.2 Hz,
2H)
6.61–6.68 (m, 2H) 6.38 (dd, J¼9.0, 4.5 Hz,
2H)
6.96–7.08 (m, 2H) 6.45 (dd, J¼9.0, 4.5 Hz,
2H)
7.12–7.21 (m, 2H)
20 – 6.96–7.19 (m, 1H) – 6.63 (t, J¼7.2 Hz, 1H) – 6.73 (t, J¼7.5 Hz, 1H)
21 5.27 (s, 2H) 5.27 (s, 2H) 5.28 (s, 2H) 5.26 (s, 2H) 5.34 (s, 2H) 5.36 (s, 2H)
23–25 7.02–7.26 (m, 5H) 6.96–7.19 (m, 5H) 7.05–7.12 (m, 5H) 6.96–7.08 (m, 5H) 7.09–7.27 (m, 5H) 7.12–7.21 (m, 5H)
27 4.55–4.62 (m, 1H); 4.67
(t, J¼8.7 Hz, 1H)
4.55–4.66 (m, 2H) 4.51–4.60 (m, 1H); 4.64
(t, J¼8.7 Hz, 1H)
4.51–4.59 (m, 1H); 4.62
(t, J¼8.7 Hz, 1H)
4.54 (t, J¼5.7 Hz, 1H);
4.69 (t, J¼8.7 Hz, 1H)
4.50–4.62 (m, 2H)
28 5.44 (dd, J¼8.4, 3.3 Hz,
1H)
5.41 (m, 1H) 5.40 (dd, J¼8.1, 1.8 Hz,
1H)
5.37 (dd, J¼8.1, 2.7 Hz,
1H)
5.45 (dd, J¼8.4, 2.4 Hz,
1H)
5.47 (d, J¼8.1 Hz, 1H)
30 7.02–7.26 (m, 5H) 7.38–7.43 (m, 2H) 7.16–7.27 (m, 4H) 7.36–7.49 (m, 2H) 7.33 (d, J¼8.7 Hz, 2H) 7.47–7.56 (m, 2H)
31 7.24–7.28 (m, 2H) 7.16–7.25 (m, 2H) 7.09–7.27 (m, 3H) 7.34–7.37 (m, 2H)
32 6.96–7.19 (m, 1H) 7.05–7.12 (m, 1H) 7.13 (dt, J¼7.2, 2.1 Hz,
1H)
7.12–7.21 (m, 1H)
33 – – 2.15 (d, J¼3.3 Hz, 1H) 2.04 (d, J¼2.4 Hz, 1H) 0.00 (s, 9H) 0.01 (s, 9H)
Assignments: s: singlet; d: doublet; t: triplet; m: multiplet; br: broad singlet. Mean values used for coupled signals.
a Numbering of all compounds shown in Fig. 2 and copies of NMR spectra are presented in Appendix A.
b Solvent is CDCl3.
E. Bellur Atici, B. Karlığa / Journal of Pharmaceutical Analysis 5 (2015) 356–370364method of ezetimibe, respectively. All the facts discussed above
clearly demonstrate that the production of stereochemically highly
pure ﬁnal products was ensured.
3.2. Detection and identiﬁcation of desﬂuoro impurity
A typical analytical HPLC chromatogram of a production batch
of ezetimibe bulk drug spiked with desﬂuoro impurity (system
suitability solution) is shown in Fig. 1A. The impurity was detected
in the ﬁnal drug substance during process development studies
and its identiﬁcation was done by LC–MS. The ESI mass spectrum
of the impurity observed at 18.05 min (RRT 0.97) exhibited a
molecular ion at m/z 392 in positive ion mode, indicating mole-
cular weight of 391, which was less by 18 amu than that of eze-
timibe. The difference relates to a missing ﬂuorine (19) and
addition of a hydrogen (þ1) instead. There are two possibilities to
form such an impurity in the ﬁnal product. One is potential Eze-3
desﬂuoro impurity and the second one is Eze-1 desﬂuoro impurity.
After our analytical studies, it was found that Eze-1 contained the
related desﬂuoro impurity and Eze-3 did not. So, the related des-
ﬂuoro impurity was subsequently synthesized to obtain sufﬁcient
quantity for full characterization and further analytical studies.
The synthesized impurity was co-injected with ezetimibe to con-
ﬁrm its identity based on the retention time matching. The im-
purity at 18.05 min (RRT 0.97) was well resolved from ezetimibe
and the HPLC method was validated accordingly.
3.3. Formation of desﬂuoro impurity and structure elucidations
Solubility of desﬂuoro ezetimibe impurity is very similar to thatof ezetimibe and it was not possible to remove this impurity by
recrystallization processes. That is why its formation should be
kept under control from the beginning of the ezetimibe produc-
tion process. The source of this impurity is desﬂuoro Eze-1, which
is found in the intermediate Eze-1. As shown in Scheme 1, Eze-1
and desﬂuoro Eze-1 and their corresponding intermediates are
similarly reacting under the same synthetic conditions. So, to keep
the amount of desﬂuoro impurity within the speciﬁed known
impurity limits (0.15%) in the ﬁnal product, the amount of des-
ﬂuoro Eze-1 should be kept below 0.15% in Eze-1. To be on the safe
side, the limit of desﬂuoro Eze-1 was speciﬁed as 0.10% in Eze-1;
an HPLC method for related substances was developed and vali-
dated accordingly. Chromatogram of system suitability solution
where Eze-1 was spiked with its related substances is given in
Fig. 1B.
Synthesis of ezetimibe was done by using 0.08% desﬂuoro Eze-
1 containing Eze-1 intermediate, resulting in formation of 0.05% of
desﬂuoro ezetimibe impurity. Purity, melting range, IR and mass
data of the synthesized compounds (Fig. 2) are listed in Table 1.
Also, UPLC chromatograms of Eze-5, Eze-6 and Eze-7 spiked with
their related desﬂuoro impurities are shown in Fig. 3.
1H and 13C NMR assignments for the structures given in Fig. 2
are shown in Tables 2–5. Compared with ezetimibe and its
intermediates, 1H NMR spectra of desﬂuoro compounds showed
one more proton peak in the aromatic region. Also, a very dramatic
difference could be seen on 13C NMR shifts where ﬂuorine splitting
was clearly seen on eight different aromatic carbons and in the
case of desﬂuoro compounds only four of themwere observed and
others did not split due to a regular C–H bonding. 19F NMR spec-
trum of ezetimibe showed two multiplets at 116.40 and
Table 5
13C NMR chemical shifts for intermediates of ezetimibe and desﬂuoro ezetimibe impurity.
Positiona δ ppm (DEPT)
Eze-5b Desﬂuoro Eze-5b Eze-6b Desﬂuoro Eze-6b Eze-7b Desﬂuoro Eze-7b
1 175.0 (C) 175.0 (C) 175.2 (C) 175.2 (C) 174.9 (C) 175.0 (C)
2 47.6 (CH) 47.5 (CH) 48.1 (CH) 48.0 (CH) 48.2 (CH) 48.1 (CH)
3 25.5 (CH2) 25.6 (CH2) 27.1 (CH2) 27.1 (CH2) 27.2 (CH2) 27.3 (CH2)
4 36.6 (CH2) 36.6 (CH2) 36.5 (CH2) 36.5 (CH2) 38.2 (CH2) 38.2 (CH2)
5 198.0 (C) 198.0 (C) 73.6 (CH) 73.6 (CH) 74.0 (CH) 74.0 (CH)
6 133.1 (d, 4J¼3.2 Hz, C) 133.1 (d, 4J¼3.2 Hz, C) 140.1 (d, 4J¼3.2 Hz, C) 140.0 (d, 4J¼3.2 Hz, C) 140.6 (d, 4J¼2.9 Hz, C) 140.6 (d, 4J¼3.2 Hz, C)
7 131.0 (d, 3J¼9.2 Hz,
2CH)
131.0 (d, 3J¼9.5 Hz,
2CH)
127.8 (d, 3J¼8.0 Hz,
2CH)
127.8 (d, 3J¼8.0 Hz,
2CH)
127.4 (d, 3J¼7.7 Hz,
2CH)
127.5 (d, 3J¼8.0 Hz, 2CH)
8 116.1 (d, 2J¼22 Hz, 2CH) 116.0 (d, 2J¼22 Hz, 2CH) 115.9 (d, 2J¼22 Hz, 2CH) 115.6 (d, 2J¼22 Hz, 2CH) 115.6 (d, 2J¼22 Hz, 2CH) 115.1 (d, 2J¼21 Hz, 2CH)
9 166.0 (d, 1J¼253 Hz, C) 166.0 (d, 1J¼253 Hz, C) 162.5 (d, 1J¼244 Hz, C) 162.4 (d, 1J¼244 Hz, C) 162.0 (d, 1J¼243 Hz, C) 162.0 (d, 1J¼243 Hz, C)
11 61.2 (CH) 59.8 (CH) 61.1 (CH) 59.7 (CH) 61.4 (CH) 60.1 (CH)
12 138.4 (C) 138.3 (C) 138.4 (C) 138.3 (C) 138.3 (C) 138.2 (C)
13 129.3 (2CH) 129.4 (2CH) 129.3 (2CH) 129.4 (2CH) 129.0 (2CH) 129.2 (2CH)
14 121.6 (2CH) 121.5 (2CH) 121.6 (2CH) 121.5 (2CH) 121.3 (2CH) 121.2 (2CH)
15 154.6 (C) 154.5 (C) 154.7 (C) 154.6 (C) 154.5 (C) 154.4 (C)
16 150.6 (C) 150.5 (C) 150.6 (C) 150.5 (C) 150.4 (C) 150.3 (C)
17 142.7 (d, 4J¼1.7 Hz, C) 146.4 (C) 142.8 (d, 4J¼1.7 Hz, C) 146.4 (C) 142.5 (d, 4J¼1.7 Hz, C) 146.2 (C)
18 115.1 (d, 3J¼7.2 Hz,
2CH)
113.9 (2CH) 115.2 (d, 3J¼7.4 Hz,
2CH)
113.9 (2CH) 115.0 (d, 3J¼7.1 Hz,
2CH)
113.8 (2CH)
19 115.9 (d, 2J¼22 Hz, 2CH) 129.3 (2CH) 115.7 (d, 2J¼22 Hz, 2CH) 129.3 (2CH) 115.1 (d, 2J¼22 Hz, 2CH) 129.0 (2CH)
20 156.4 (d, 1J¼234 Hz, C) 118.0 (CH) 156.3 (d, 1J¼234 Hz, C) 118.0 (CH) 156.1 (d, 1J¼234 Hz, C) 117.8 (CH)
21 70.3 (CH2) 70.3 (CH2) 70.3 (CH2) 70.2 (CH2) 70.1 (CH2) 70.0 (CH2)
22 134.9 (C) 134.9 (C) 134.9 (C) 134.9 (C) 134.8 (C) 134.8 (C)
23 128.9 (2CH) 128.8 (2CH) 128.9 (2CH) 128.8 (2H) 128.7 (2CH) 128.7 (2CH)
24 129.0 (2CH) 129.0 (2CH) 129.0 (2CH) 129.0 (2CH) 128.8 (2CH) 128.8 (2CH)
25 129.1 (CH) 129.1 (CH) 129.1 (CH) 129.1 (CH) 128.9 (CH) 128.9 (CH)
26 153.7 (C) 153.7 (C) 153.8 (C) 153.8 (C) 153.5 (C) 153.5 (C)
27 70.7 (CH2) 70.6 (CH2) 70.7 (CH2) 70.6 (CH2) 70.4 (CH2) 70.4 (CH2)
28 58.4 (CH) 58.3 (CH) 58.4 (CH) 58.3 (CH) 58.2 (CH) 58.1 (CH)
29 138.5 (C) 138.6 (C) 138.7 (C) 138.9 (C) 138.6 (C) 138.7 (C)
30 125.6 (2CH) 125.5 (2CH) 125.6 (2CH) 125.5 (2CH) 125.3 (2CH) 125.3 (2CH)
31 128.2 (2CH) 128.3 (2CH) 128.3 (2CH) 128.2 (2CH) 128.1 (2CH) 128.1 (2CH)
32 128.6 (CH) 128.6 (CH) 128.6 (CH) 128.5 (CH) 128.4 (CH) 128.3 (CH)
33 – – – – 0.0 (3CH3) 0.0 (3CH3)
a Numbering of all compounds shown in Fig. 2 and copies of NMR spectra are presented in Appendix A. Mean values used for coupled signals.
b Solvent is CDCl3.
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C-20 (Fig. 4), respectively. As expected, desﬂuoro ezetimibe
showed one multiplet at 116.43 ppm corresponding to the
ﬂuorine atom on C-9. All spectral data (Supplementary Appendix
A) conﬁrmed the structures of desﬂuoro impurities synthesized in
scope of this study.
3.4. Validation of HPLC methods
Methods were validated according to ICH Q2 (R1) guideline
[40].
3.4.1. Validation of Eze-1 related substances method
Related substances limits for Eze-1 are speciﬁed as follows:
4-hydroxy benzaldehyde not more than 0.50%, 4-ﬂuoroaniline not
more than 0.50%, desﬂuoro Eze-1 not more than 0.10%, any other
impurity not more than 0.30% and total impurities not more than
1.0% and validated accordingly. Purities of reference standards
used during the validation study are as follows: Eze-1 99.7%,
4-hydroxybenzaldehyde 99.8%, 4-ﬂuoroaniline 99.8%, and des-
ﬂuoro Eze-1 99.7%.
The system suitability was conducted throughout the valida-
tion study by using 1.2 μg/mL of Eze-1 reference solution and
evaluated by making six replicate injections. The system was
deemed to be suitable for use as the relative standard deviation
(RSD) of the areas was found below 5.0%, resolution above 2.0 (4.6)
and symmetry factor below 1.5 (1.1). Average of the areas was
found as 44,117 with standard deviation (SD) 459 and RSD wascalculated as 1.0%, conﬁrming the injection repeatability of the
developed method.
The following injections were done for speciﬁcity test: two
diluents, two from each impurity at speciﬁcation limit, two from
mixture of impurities at speciﬁcation limit, two test solutions
(0.4 mg/mL Eze-1), and two test solutions spiked with impurities
at speciﬁcation limit. No interference was observed in the chro-
matogram of diluent where Eze-1 and its impurities peaks elute.
Purity angles of Eze-1 and all impurities peaks (0.25, 0.46, 1.04,
and 1.76, respectively) were found less than purity thresholds
(0.85, 0.65, 1.23, and 1.97, respectively). Thus, the method was
found speciﬁc for determination of the related substances in Eze-1.
Stability of solutions was evaluated by injection of two re-
ference solutions and two test solutions freshly and then each 24 h
during two days. Reference and test solutions were accepted as
stable for a time period during which the absolute differences
between fresh and different period results were below 0.10% and
0.05%, respectively. This difference did not exceed 0.01% and 0.04%,
respectively for both solutions with RSD value of 0.7% and they
were found stable up to 48 h. At longer time periods, amounts of
4-hydroxybenzaldehyde and 4-ﬂuoroaniline impurities were in-
creased due to the dissociation of Eze-1 to its starting materials.
Limit of detection (LOD) and limit of quantitation (LOQ) values
were calculated according to the following equations: LOD¼3
(BN/H)C; LOQ¼10 (BN/H)C, where BN is baseline-noise
(mV), H is height (mV) and C is concentration of the reference
solution (mg/mL). Six replicate diluent injections were done for
baseline noise calculations, and solution containing Eze-1 RS and
Fig. 4. Comparison of 1H, 13C and 19F NMRs of ezetimibe and desﬂuoro ezetimibe impurity.
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calculation of peak heights. LOD and LOQ values for Eze-1, 4-hy-
droxybenzaldehyde, 4-ﬂuoroaniline and desﬂuoro Eze-1 were
found to be 0.003% (0.013 mg/mL), 0.003% (0.010 mg/mL), 0.004%
(0.014 mg/mL), 0.003% (0.011 mg/mL), and 0.011% (0.042 mg/mL),
0.008% (0.032 mg/mL), 0.012% (0.046 mg/mL), 0.010% (0.038 mg/mL),
respectively. LOQ values were below the reported level 0.05% with
RSD of 0.3%, 0.3%, 0.2% and 0.2%, respectively. Signal to noise ratios
at LOD and LOQ concentrations were found below 3 and 10, re-
spectively, and met the validation criterion. Precision at LOQ level
was done by six replicate injections of Eze-1 RS and impurities
solution prepared at LOQ concentration. Averages of the areas
were found as 1357, 1225, 1399 and 1343 with standard deviation
of 61, 60, 94, and 83, and RSD of 4.5%, 4.9%, 6.7%, and 6.2%, re-
spectively, which were below the acceptance limit of 10.0%. Cor-
rection response factors (CRF) were calculated according to the
following equation: CRF¼(ACi)/(AiC), where A is peak area of
Eze-1, Ai is peak area of the impurity, C is concentration of Eze-1
(mg/mL), and Ci is concentration of the impurity (mg/mL). CRFs for
4-hydroxybenzaldehyde, 4-ﬂuoroaniline and desﬂuoro Eze-1 were
found as 1.1, 1.3, and 0.9, respectively. Chromatograms of diluent,
system suitability solution, reference and test solutions, mixture
solution of all impurities and test solution spiked with all im-
purities at speciﬁcation limits, LOD and LOQ solutions are given in
Fig. 5.
Linearity test solutions of Eze-1 RS and its impurities were
prepared at ﬁve concentration levels ranging from disregard limit
(DL) to 150% of the speciﬁcation limit and each sample was in-
jected three times. The peak area versus concentration data was
analyzed with least squares linear regression. Correlation coefﬁ-
cient (r) and y-intercept ratio to the response of target con-
centration were found as 1.0000, 0.9999, 0.9993, 0.9993 (Z0.99)
and 0.24%, 0.95%, 0.45%, 0.41% (r5.0%), respectively, indicatingthe good linearity of the method. Solutions at level 1 (DL) and level
5 (150% of speciﬁcation limit) were injected six times, and RSD
values of areas were calculated for range study, and found to be
0.7%, 1.3%, 1.3%, 0.8% for level 1 and 0.5%, 0.6%, 0.4%, 0.8% for level
5, respectively, below the acceptance limits of 7.0% and 5.0%.
The accuracy of the method was evaluated on test solutions
spiked with Eze-1 impurities in triplicate at three concentration
levels of 50%, 100% and 150% of the speciﬁcation limit. Good-to-
excellent recoveries of the impurities (98.63–104.2%) at each level
were achieved within the limit range of 90.0–110.0% (Table 6).
RSDs of recoveries were found below 5.0%, as 2.0%, 2.6%, and 2.0%,
respectively.
The precision of the method was investigated by injecting six
individual test solutions of Eze-1 (0.4 mg/mL). The same procedure
was applied for the inter-day precision by a different analyst using
different batch column and different instrument located within
the same laboratory. The system suitability results for the intra-
day and inter-day precision studies were obtained as RSD 3.0% and
0.2%, resolution 4.6 and 3.7, symmetry factor 1.1 and 1.2, respec-
tively. Results obtained for RSD were below 5.0% in both studies
(Table 6) and difference between mean of results of two studies
was found below 0.05% (absolute value), and the method was
found to be sufﬁciently precise since no signiﬁcant variation in the
found amounts was observed on any day.
Robustness of the method was tested by changing column, ﬂow
rate by 710% (1.170.1 mL/min), buffer pH by 70.2 units
(7.570.2), column temperature by 73 °C (3073 °C), and acet-
onitrile content of mobile phase A by 75% (4075%). System
suitability parameters were fulﬁlled in all of the above varied
chromatographic conditions. Difference between the results of
normal and altered conditions did not exceed 0.01% (o0.05%),
indicating the robustness of the method.
Requirements for each stage of the validation study were
Fig. 5. Chromatograms of (A) diluent, (B) reference solution, (C) system suitability solution, (D) solution of impurities at speciﬁcation limit, (E) test solution, (F) test solution
spiked with impurities at speciﬁcation limit, (G) LOD solution, and (H) LOQ solution of Eze-1 related substances HPLC method validation.
E. Bellur Atici, B. Karlığa / Journal of Pharmaceutical Analysis 5 (2015) 356–370 367fulﬁlled. Thus, our method was found precise, linear, accurate,
sensitive, selective and robust, and could be used for related
substances analysis of Eze-1. This method was used in routine
productions of ezetimibe to control impurities in the intermediate
Eze-1 and keep the drug substance impurity content in acceptable
range.3.4.2. Validation of ezetimibe related substances method
Related substances limits for ezetimibe are speciﬁed as follows:
desﬂuoro ezetimibe not more than 0.15%, any impurity in-
dividually not more than 0.10% and total impurities not more than
0.5% and validated accordingly. Purities of reference standards
used during the validation study are as follows: ezetimibe 99.9%
and desﬂuoro ezetimibe 97.9%.
Table 6
Accuracy and precision studies of the HPLC method for determination of Eze-1 related substances.
Compound Accuracy (n¼3) Precision
Intra-day (n¼6) Inter-day (n¼6)
Amount in test
soln. (%)
Amount theo.
(Mean, %)
Amount found
(Mean7SD, %)
RSD (%) Recovery (%) Amount found
(Mean7SD, %)
RSD (%) Amount found
(Mean7SD, %)
RSD (%)
4-Hydroxy
benzaldehyde
0.094 0.242 0.24570.008 3.2 100.9 0.1070.004 4.0 0.1070.004 4.0
0.492 0.49570.009 1.8 100.5
0.735 0.74070.009 1.2 100.7
4-Fluoroaniline 0.014 0.261 0.26370.003 1.2 100.9 0.0270.00 0.0 0.0270.00 0.0
0.513 0.52170.007 1.3 101.5
0.756 0.78770.031 3.9 104.2
Desﬂuoro Eze-1 0.077 0.077a 0.07670.001 1.5 NA 0.0870.00 0.0 0.0870.00 0.0
0.097 0.09670.0006 0.60 98.63
0.146 0.14970.001 0.67 102.1
a Not spiked. NA: not applicable.
E. Bellur Atici, B. Karlığa / Journal of Pharmaceutical Analysis 5 (2015) 356–370368System suitability was conducted throughout the validation
study by using ezetimibe standard solution in concentration of
1.0 mg/mL and evaluated by making six replicate injections. The
system was accepted to be suitable for use as RSD of areas was
below 5.0%, symmetry factor in the range of 0.8–1.5, and the re-
solution between peaks of ezetimibe and desﬂuoro ezetimibe was
below 2.0. Average of the areas was found as 14,165 with standard
deviation of 411. RSD of areas, symmetry factor and resolution
were found as 2.90%, 1.0 and 3.5, respectively, conﬁrming the
system suitability of the developed method.
Speciﬁcity test was carried out by injections of three diluents,
and two from each of the following solutions: test, desﬂuoro
ezetimibe at speciﬁcation limit and test solution spiked with
desﬂuoro ezetimibe at speciﬁcation limit (0.10%). No peak was
observed on diluent chromatogram at the retention time of eze-
timibe and desﬂuoro ezetimibe. Purity angles of ezetimibe and
desﬂuoro ezetimibe peaks were found less than purity thresholds.
Stability of reference solution was evaluated by injection of two
different reference solutions freshly and then each 24 h during
two days. Stability of test solutions was evaluated by injection of
two different sample solutions freshly and then each 3 h during
24 h. Solutions were accepted as stable for a time period during
which the difference between fresh and different period results
was below 0.05%. The reference and test solutions were found
stable up to 48 h and 24 h, respectively.
The LOD and LOQ for ezetimibe and desﬂuoro ezetimibe were
estimated at a signal-to-noise ratio of 3:1 and 10:1, respectively, by
injecting six replicate diluent and solution containing ezetimibe
and desﬂuoro ezetimibe at 1 μg/mL concentration. The LOD and
LOQ for ezetimibe and desﬂuoro ezetimibe were found 0.012%
(0.12 μg/mL), 0.013% (0.13 μg/mL) and 0.041% (0.41 μg/mL), 0.043%
(0.43 μg/mL), respectively. LOD and LOQ signal to noise ratios were
found to be 3.4, 3.1 (Z3) and 10.7, 10.4 (Z10), respectively. LOQ
was found below the reported level 0.05% and met the validation
criterion. Precision at the LOQ level was done by injecting six re-
plicates of solution containing ezetimibe and desﬂuoro ezetimibe
at LOQ concentration. Average of the areas for ezetimibe and
desﬂuoro ezetimibe was found as 4879 and 5171 with standard
deviation of 65 and 52, and RSD value of 1.3% and 1.0%, which were
below the acceptance limit of 10.0%. CRF was calculated according
to the following equation: CRF¼(ACi)/(AiC), where A is peak
area of ezetimibe, Ai is peak area of desﬂuoro impurity, C is con-
centration of ezetimibe (1 mg/mL), and Ci is concentration of des-
ﬂuoro impurity (1 mg/mL). RSD of the peak areas was found to be
1.7% and CRF for desﬂuoro impurity was calculated as 1.01. Chro-
matograms of diluent, system suitability solution, reference and
test solutions, desﬂuoro impurity and test solution spiked withdesﬂuoro impurity at speciﬁcation limit (0.15%), LOD and LOQ
solutions are given in Fig. 6.
Linearity test solutions were prepared at ﬁve concentration
levels ranging from DL to 120% of the speciﬁcation limit (0.15%)
and each sample was injected three times. The peak area versus
concentration data was analyzed with least squares linear re-
gression. Correlation coefﬁcient (r) and y-intercept ratio to the
response of target concentration for ezetimibe and desﬂuoro im-
purity were found as 0.9930, 0.9998 (above 0.99) and 0.94%, 1.72%
(below 5.0%), respectively, indicating the good linearity of the
method. Solutions at level 1 and level 5 were injected six times
and RSDs of ezetimibe and desﬂuoro ezetimibe peak areas were
calculated for range study, and found as 1.8%, 1.0% and 0.6%, 0.4%,
respectively, below the acceptance limit of 10.0% and 5.0%.
The accuracy of the method was evaluated by injection of six
desﬂuoro ezetimibe solutions at speciﬁcation limit, six different
test solutions for determination of desﬂuoro impurity content, and
three test solutions spiked with desﬂuoro ezetimibe at con-
centration levels of 80%, 100% and 120% of the speciﬁcation limit in
triple. Good-to-excellent recoveries (100.4%–100.8%) at each level
were achieved within the limit range of 90.0%–110.0% (Table 7).
RSD of recoveries and RSD of desﬂuoro ezetimibe peak areas for
six replicate injections were found as 1.4% (below 5.0%) for both.
The method precision of an analytical procedure expresses the
close agreement between single results of the method applied
repeatedly by the same analyst, using the homogeneous sample,
the same instrumentation and same reagents. The precision of the
method was investigated by injecting six individual test solutions.
The inter-day precision was conducted according to the same
procedure on a different day by a different analyst using different
batch column and different instrument located in the same la-
boratory. No difference was found between the results of intra-day
and inter-day precision studies and the amount of desﬂuoro
impurity was found to be 0.09% with RSD of 0.0% on both days
(Table 7), indicating the precision of the method.
The robustness of an analytical method is a measure of the
effect of variable conditions on analytical results in the process of
analysis. For the determination of the method’s robustness, ﬂow
rate, pH of the buffer and column temperature were varied within
realistic range and the effect of variations on analytical procedure
was examined and reported. Robustness of the method was tested
by changing ﬂow rate (1.370.13 mL/min), buffer pH (3.070.3),
and column temperature (3573.5 °C) by 710%. In all of the above
varied chromatographic conditions, RSD and symmetry factors
were found in the range of 1.5%–2.8% and 0.8–1.0, respectively. No
difference was found between the results of normal and altered
conditions, suggesting the robustness of the method.
Fig. 6. Chromatograms of (A) diluent, (B) reference solution, (C) system suitability solution, (D) solution of desﬂuoro ezetimibe impurity at speciﬁcation limit, (E) test
solution, (F) test solution spiked with desﬂuoro ezetimibe impurity at speciﬁcation limit (0.15%), (G) LOD solution (ezetimibe 0.12 μg/mL (0.012%) and desﬂuoro impurity
0.13 μg/mL (0.013%)), and (H) LOQ solution (ezetimibe 0.41 μg/mL (0.041%) and desﬂuoro impurity 0.43 μg/mL (0.043%)) of ezetimibe related substances HPLC method
validation.
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validation study and the results showed that our developed
method is speciﬁc, linear, precise, accurate and robust, and it could
be used for related substances analyses of ezetimibe manufactur-
ing batches. This method was used in routine productions and
stability testing of ezetimibe drug substance. The mount of des-
ﬂuoro impurity in ezetimibe was found below the speciﬁed limit
and as expected it was not affected during the stability studies
since it was not a degradation product.4. Conclusion
In conclusion, a process related impurity of ezetimibe, pro-
duced according to the synthetic route given in Scheme 1, was
identiﬁed, synthesized and characterized. Structural elucidations
of all synthesized compounds were done by using NMR (1H, 13C,
DEPT, 19F), IR and MS spectral data. Thus, the regulatory require-
ment was fulﬁlled by characterizing this impurity and the pre-
pared impurity standard was used during analytical method
Table 7
Accuracy and precision studies of the HPLC method for determination of ezetimibe related substances.
Compound Accuracy (n¼3) Precision
Intra-day (n¼6) Inter-day (n¼6)
Amount in
test soln. (%)
Spiked
conc.
(mg/mL)
Amount theo.
(Mean, %)
Amount found
(Mean7SD, %)
RSD (%) Recovery (%) Amount found
(Mean7SD, %)
RSD (%) Amount found
(Mean7SD, %)
RSD (%)
Desﬂuoro
ezetimibe
0.028 0.1882 0.120 0.12170.003 2.2 100.8 0.0970.00 0.0 0.0970.00 0.0
0.4690 0.147 0.14870.003 2.0 100.7
0.7499 0.174 0.17470.001 0.66 100.4
E. Bellur Atici, B. Karlığa / Journal of Pharmaceutical Analysis 5 (2015) 356–370370validation studies. This work also supported the optimization
stage of the process development and enabled us to see and
control the critical points of the process. The knowledge of the
impurity source (Eze-1) helped us to control the amount of des-
ﬂuoro Eze-1 impurity by a newly developed and validated HPLC
method, which allowed us to reduce the desﬂuoro ezetimibe im-
purity successfully even below 0.10% in the ﬁnal drug substance.Acknowledgments
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